Literature DB >> 17255133

Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies.

S Sato1, M Kuwana, M Hirakata.   

Abstract

OBJECTIVES: The clinical and laboratory characteristics of seven patients with anti-aminoacyl-tRNA synthetase (ARS) autoantibodies, specifically anti-OJ (anti-isoleucyl-tRNA synthetase), were examined and compared with previously published findings.
METHODS: Serum samples from 1135 Japanese patients with various autoimmune diseases and 48 normal individuals were screened for anti-OJ antibodies using RNA and protein immunoprecipitation assays. The patients whose sera contained anti-OJ antibodies were assessed regarding clinical symptoms, clinical course, laboratory findings, chest radiography and chest computed tomography.
RESULTS: Sera from seven patients were found to contain anti-OJ antibodies. These autoantibodies were associated with interstitial lung disease (ILD) and myositis. The diagnoses of the seven patients were idiopathic interstitial pneumonias (IIPs) in three, polymyositis (PM) in three and PM-rheumatoid arthritis (RA) overlap in the remaining one. All patients had ILD, but muscle weakness and polyarthritis were seen only in four. Raynaud's phenomenon and sclerodactyly were absent in all patients.
CONCLUSIONS: These results indicate that the presence of anti-OJ autoantibodies may distinguish a subtype of anti-ARS syndrome that is more closely associated with ILD than myositis or Raynaud's phenomenon.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17255133     DOI: 10.1093/rheumatology/kel435

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  22 in total

1.  Antisynthetase syndrome associated with long-standing rheumatoid arthritis.

Authors:  Takao Nagashima; Masahiro Iwamoto; Seiji Minota
Journal:  Rheumatol Int       Date:  2010-03-30       Impact factor: 2.631

2.  Dermatomyositis with anti-OJ antibody.

Authors:  Shinji Noda; Yoshihide Asano; Zenshiro Tamaki; Megumi Hirabayashi; Mizuho Yamamoto; Tomonori Takekoshi; Toshihiko Hoashi; Makoto Sugaya; Rieko Morimoto; Takafumi Etoh; Kenzo Kaji; Manabu Fujimoto; Masataka Kuwana; Shinichi Sato
Journal:  Rheumatol Int       Date:  2010-12-05       Impact factor: 2.631

Review 3.  Myositis-related interstitial lung disease and antisynthetase syndrome.

Authors:  Joshua Solomon; Jeffrey J Swigris; Kevin K Brown
Journal:  J Bras Pneumol       Date:  2011 Jan-Feb       Impact factor: 2.624

Review 4.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

5.  Heterogeneous clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case series.

Authors:  Margherita Giannini; Antonella Notarnicola; Maryam Dastmalchi; Ingrid E Lundberg; Giuseppe Lopalco; Florenzo Iannone
Journal:  Clin Rheumatol       Date:  2016-04-11       Impact factor: 2.980

Review 6.  Clinical heterogeneity and outcomes of antisynthetase syndrome.

Authors:  Baptiste Hervier; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2013-08       Impact factor: 4.592

Review 7.  The evolving spectrum of polymyositis and dermatomyositis--moving towards clinicoserological syndromes: a critical review.

Authors:  Sarah Tansley; Harsha Gunawardena
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

8.  Autoantibodies and their significance in myositis.

Authors:  Ira N Targoff
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

9.  Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients.

Authors:  Rohit Aggarwal; Elaine Cassidy; Noreen Fertig; Diane Carol Koontz; Mary Lucas; Dana P Ascherman; Chester V Oddis
Journal:  Ann Rheum Dis       Date:  2013-02-19       Impact factor: 19.103

Review 10.  Inflammatory muscle disease: clinical presentation and assessment of patients.

Authors:  Helene Alexanderson; Ingrid E Lundberg
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.